<DOC>
	<DOCNO>NCT01594177</DOCNO>
	<brief_summary>Anthracycline/taxane base combination chemotherapy least 18 week represent standard care neoadjuvant setting . In HER2 positive disease trastuzumab give simultaneously . Neoadjuvant anthracycline-taxane-based chemotherapy give simul-taneously trastuzumab achieves pCR rate approx . 40 % . Recent data show double blockade HER2 receptor ( e.g . trastuzumab + lapatinib ; trastuzumab + pertuzumab ) give together cycle chemotherapy increase pCR rate approximately 20 % . So far , uncertainty , afatinib ( BIBW 2992 ) , irreversible HER family blocker lead even complete blockade HER2 pathway give combination trastuzumab . The neoadjuvant setting provide unique opportunity ass precisely short term effect systemic treatment assess pCR surgery . It also allow treat patient HER2 positive breast cancer surgery without standard trastuzumab treatment , , accord current guideline , trastuzumab also give sequentially surgery . The aim study show chemotherapy + trastuzumab + afatinib achieve significant pCR rate .</brief_summary>
	<brief_title>Dual Blockage With Afatinib Trastuzumab Neoadjuvant Treatment Patients With Locally Advanced Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy</brief_title>
	<detailed_description>Primary objective : To compare pathological complete response ( pCR = ypT0/is ypN0 ) rate neoadjuvant treatment afatinib combination weekly paclitaxel + trastuzumab follow epirubicin/ cyclophosphamide/ trastuzumab patient HER2-positive primary breast cancer . Secondary objective : To determine rate ypT0 ypN0 ; ypT0 ; ypT0/is ; ypN0 ; regression grade accord Sinn . To determine response rate breast tumor axillary node physical examination imaging test ( sonography , mammography , MRI ) 6 week 2 anti-HER2 agent alone surgery . To determine breast axilla conservation rate treatment . To assess toxicity compliance . To correlate skin toxicity diarrhoea pCR . To examine compare pre-specified molecular marker EGFR , HER2 , HER3 , HER4 , TGFß , EGF , AREG , HBEGF , BTC , EPIGEN , EREG , NRG1 , NRG2 , neuroglycan , tomoregulin , NRG4 NRG3K-RAS , MET , IGF1R , IRS1 , PTEN , FGFR1 , FGFR2 , FGFR3 , AXL , RET , PDGFR ; EGFR signature , Ki67 , p95HER2 , PI3K mutation start afatinib+trastuzumab , chemotherapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Written inform consent study procedure accord local regulatory requirement prior begin specific protocol procedure . 2 . Complete baseline documentation must send GBG Forschungs GmbH . 3 . Unilateral primary carcinoma breast , confirm histologically core biopsy . Fineneedle aspiration sufficient . Incisional biopsy allow . Tumor lesion breast sonographical size ≥ 2 cm maximum diameter . The lesion measurable two dimension , preferably sonography . In case inflammatory disease , extent inflammation use measurable lesion . 4 . Operable locally advanced inflammatory breast cancer ( cT2 cT4ad ) . In patient multifocal multicentric breast cancer , large lesion measure . 5 . Centrally confirm positive HER2 status detect core biopsy . HER2positive define IHC 3+ validate test method FISH/SISH ratio &gt; 2.0 . Formalinfixed , paraffinembedded ( FFPE ) breast tissue core biopsy therefore send Department Pathology Charité , Berlin , prior regsitration . 6 . Centrally confirm hormone receptor status ( ER/PgR ) . 7 . Age ≥ 18 year . 8 . Karnofsky Performance status ≥ 80 % . 9 . Normal cardiac function must confirm ECG cardiac ultrasound ( LVEF shorten fraction ) within 3 month prior registration . Results must 55 % . 10 . Laboratory requirement : Hematology Absolute neutrophil count ( ANC ) ≥ 2.0 x 109/L Platelets ≥ 100 x 109/L Hemoglobin ≥ 10 g/dL ( ≥ 6.2 mmol/L ) Hepatic function Total bilirubin ≤ 1.5x UNL ASAT ( SGOT ) ALAT ( SGPT ) ≤ 1.5x UNL Alkaline phosphatase ≤ 2.5x UNL . Renal function Creatinine ≤ 175 µmol/L ( 2 mg/dL ) &lt; 1.5x UNL . 11 . Negative pregnancy test ( urine serum ) within 14 day prior registration woman childbearing potential . 12 . Complete stag workup within 3 month prior registration . All patient must bilateral mammography , breast ultrasound ( ≤ 21 day ) , breast MRI ( optional ) , chest Xray ( PA lateral ) , abdominal ultrasound CT scan MRI , bone scan do . In case positive bone scan , bone Xray mandatory . Other test may perform clinically indicate . 13 . Patients must available compliant treatment followup . Patients register trial must treat participate cooperate centre . 1 . Bilateral breast cancer . 2 . Prior chemotherapy malignancy . 3 . Prior radiation therapy breast cancer . 4 . Pregnant lactating patient . Patients childbearing potential must implement adequate nonhormonal contraceptive measure ( barrier method , intrauterine contraceptive device , sterilisation ) study treatment . 5 . Inadequate general condition ( fit anthracyclinetaxane base chemotherapy ) per investigator´s assessment . 6 . Previous malignant disease diseasefree period le 5 year ( except CIS cervix nonmelanomatous skin cancer ) . 7 . Known preexist interstitial lung disease . 8 . Known suspected congestive heart failure ( NYHA &gt; I ) coronary heart disease , angina pectoris require antianginal medication , previous history myocardial infarction , evidence transmural infarction ECG , uncontrolled poorly control arterial hypertension ( i.e . BP &gt; 160/90 mm Hg treatment two antihypertensive drug ) , rhythm abnormality require permanent treatment , clinically significant valvular heart disease . 9 . History significant neurological psychiatric disorder include psychotic disorder , dementia seizure would prohibit understanding give informed consent . 10 . Chronicinflammatory bowel disease . 11 . Preexisting motor sensory neuropathy severity grade ≥ 2 NCICTCAE criterion . 12 . No evidence history infection ( include hepatitis B , C HIV ) . 13 . Known hypersensitivity reaction one investigational compound incorporated substance use protocol . 14 . Definite contraindication use corticosteroid except inhalative corticoid . 15 . Concurrent treatment : chronic corticosteroid unless initiate &gt; 6 month prior study entry low dose ( ≤ 10 mg methylprednisolone equivalent ) . sex hormone . Prior treatment must stop study entry . experimental drug anticancer therapy . 16 . Participation another clinical trial investigational , market drug within 30 day prior study entry . 17 . Male patient .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>DAFNE</keyword>
	<keyword>GBG 70</keyword>
	<keyword>GBG</keyword>
	<keyword>German Breast Group</keyword>
	<keyword>GBG Forschungs GmbH</keyword>
	<keyword>Afatinib</keyword>
	<keyword>neo-adjuvant</keyword>
	<keyword>HER-2 positive breast cancer</keyword>
	<keyword>BIBW 2992</keyword>
	<keyword>1200.159</keyword>
</DOC>